By Christy Santhosh (Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate ...

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed ...

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

(Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce ...

Electronic reminders to encourage older adults in Denmark to get vaccinated against flu may have unintentionally lowered ...

The launch of our '24-'25 season updated COVID-19 vaccine in August. Novavax successfully operationalizing our partnership with Sanofi, which enabled them last month to assume lead commercial ...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical trials.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

Vaccines Market Growth, Share Herpes simplex virus (HSV) is known for causing herpes infection. This is majorly ...

The growth trajectory of the global generic drugs market is underpinned by several key drivers. Firstly, the escalating incidence of chronic and non-chronic diseases worldwide underscores the vital ...